Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Rhea-AI Summary

Syndax Pharmaceuticals (Nasdaq: SNDX) granted inducement awards on December 1, 2025 to a newly hired employee under its 2023 Inducement Plan.

The awards permit purchase of up to 15,500 shares of common stock. Options vest over a four-year schedule: 25% of the shares vest on the one-year anniversary of the vesting commencement date, then 1/48th of the shares vest monthly for the remaining 36 months, subject to continued service.

News Market Reaction – SNDX

+0.15%

1 alert

+0.15% News Effect

On the day this news was published, SNDX gained 0.15%, reflecting a mild positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

Key Figures

Inducement options: 15,500 shares Vesting period: 4 years Cliff vesting portion: 25% +2 more

5 metrics

Inducement options 15,500 shares Stock options granted to one new employee on December 1, 2025

Vesting period 4 years Total vesting duration for the inducement stock options

Cliff vesting portion 25% Portion vesting on the one-year anniversary of vesting commencement

Monthly vesting fraction 1/48th Monthly vesting of remaining options over the following 36 months

Monthly vesting duration 36 months Period over which remaining options vest monthly

Market Reality Check

Price: $24.23 Vol: Volume 1,889,871 is at 0....

normal vol

$24.23 Last Close

Volume Volume 1,889,871 is at 0.81x the 20-day average of 2,328,548 shares normal

Technical Price $20.41 is trading above the 200-day MA at $13.37

Peers on Argus

SNDX gained 5.69% with mixed peer moves: BHVN up 6.12%, VERA up 3.96%, while ARD...

SNDX gained 5.69% with mixed peer moves: BHVN up 6.12%, VERA up 3.96%, while ARDX and VRDN were modestly negative and TRML was flat, suggesting stock-specific strength rather than a broad sector move.

Historical Context

5 past events · Latest: Dec 08 (Positive)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Dec 08	Clinical data update	Positive	-1.7%	Detailed Revuforj data from 12 ASH 2025 abstracts in acute leukemias.
Dec 03	Inducement equity grant	Neutral	+0.2%	Inducement stock options for a new hire under 2023 Inducement Plan.
Dec 01	Conference participation	Neutral	-3.5%	CEO fireside chat announced for Evercore Healthcare Conference webcast.
Nov 05	Inducement equity grant	Neutral	-2.7%	Inducement options for four new employees under 2023 Inducement Plan.
Nov 03	Earnings and update	Positive	+0.4%	Q3 2025 revenue, Revuforj launch metrics, and business update reported.

Pattern Detected

Recent news often drew muted or negative reactions, even for clearly positive clinical and regulatory updates, with only select events aligning positively with share price.

Recent Company History

Over the last few months, Syndax reported multiple milestones. On Nov 3, 2025, it posted Q3 2025 results with $45.9M revenue, including Revuforj and Niktimvo contributions, alongside a $60.7M net loss. Subsequent filings documented FDA approval of Revuforj for R/R AML and inclusion in NCCN Guidelines. The company also announced repeated inducement equity grants under its 2023 Inducement Plan and conference participation. Despite very strong Revuforj clinical data highlighted at ASH 2025, some of these fundamentally positive updates coincided with negative short-term price reactions.

Market Pulse Summary

This announcement details a routine inducement stock option grant for a new employee, covering up to...

Analysis

This announcement details a routine inducement stock option grant for a new employee, covering up to 15,500 shares under the company’s 2023 Inducement Plan. The options vest over four years, with 25% after one year and the remainder monthly over 36 months. In context of recent Revuforj approval, strong clinical data, and Q3 $45.9M revenue, investors often track how ongoing hiring and equity incentives support the commercial build-out.

Key Terms

nasdaq listing rule 5635(c)(4), inducement awards, stock options, vesting

4 terms

nasdaq listing rule 5635(c)(4) regulatory

"Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)"

NASDAQ Listing Rule 5635(c)(4) is a rule that requires a company to get approval from its shareholders before selling a large amount of its shares, usually over 20%. This helps protect investors by making sure the company doesn't flood the market with new shares without their say, which could lower the stock's value.

inducement awards financial

"the Company granted inducement awards to purchase up to 15,500 shares"

Inducement awards are special bonuses given to new employees to encourage them to join a company, often in the form of stock or money. They matter because they can motivate talented people to choose one company over another and help align their success with the company's growth. Think of it like a signing bonus to seal the deal.

stock options financial

"The stock options will vest over four years, with 25% of the underlying"

Stock options are agreements that give a person the right to buy or sell a company's stock at a specific price within a certain time frame. They are often used as a reward or incentive, similar to a coupon that can be used later if the stock price rises, allowing the holder to make a profit.

vesting technical

"25% of the underlying shares vesting on the one-year anniversary"

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

AI-generated analysis. Not financial advice.

NEW YORK, Dec. 03, 2025 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that on December 1, 2025, the Company granted inducement awards to purchase up to 15,500 shares of common stock to one new employee under the Company's 2023 Inducement Plan. The stock options will vest over four years, with 25% of the underlying shares vesting on the one-year anniversary of the vesting commencement date and 1/48th of the underlying shares vesting monthly thereafter over 36 months, subject to the employee's continued service relationship with Syndax through the applicable vesting dates.

About Syndax
Syndax Pharmaceuticals is a commercial-stage biopharmaceutical company advancing innovative cancer therapies. Highlights of the Company's pipeline include Revuforj^® (revumenib), an FDA-approved menin inhibitor, and Niktimvo™ (axatilimab-csfr), an FDA-approved monoclonal antibody that blocks the colony stimulating factor 1 (CSF-1) receptor. Fueled by our commitment to reimagining cancer care, Syndax is working to unlock the full potential of its pipeline and is conducting several clinical trials across the continuum of treatment. For more information, please visit www.syndax.com or follow the Company on X and LinkedIn.

Syndax Contact

Sharon Klahre 
Syndax Pharmaceuticals, Inc. 
sklahre@syndax.com
Tel 781.684.9827

FAQ

What did Syndax (SNDX) announce on December 3, 2025 about an inducement grant?

Syndax announced it granted inducement awards on Dec 1, 2025 to purchase up to 15,500 shares to a new employee under its 2023 Inducement Plan.

How do the Syndax (SNDX) inducement options vest?

Options vest over four years: 25% at the one-year anniversary, then 1/48th monthly for the next 36 months, subject to continued service.

How many shares did Syndax (SNDX) grant in the inducement award?

The inducement award permits purchase of up to 15,500 shares of common stock.

Under which plan were the Syndax (SNDX) inducement awards granted?

The awards were granted under Syndax's 2023 Inducement Plan.

Who received the Syndax (SNDX) inducement awards?

The awards were granted to one new employee as an inducement hire.

Will the Syndax (SNDX) inducement options vest if the employee leaves early?

Vesting is subject to the employee's continued service through each applicable vesting date, so early departure would generally forfeit unvested shares.